Lactobacillus Composition for H. pylori Eradication

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapies for Helicobacter pylori infection, including antibiotics and proton pump inhibitors, often result in side effects and antibiotic resistance, with a low eradication rate, necessitating an alternative approach to effectively treat gastritis caused by gastric Helicobacter pylori.

Innovation Solution

A pharmaceutical composition comprising Lactobacillus rhamnosus GM-020, Lactobacillus acidophilus GMNL-185, and Lactobacillus plantarum GMNL-662, administered orally or as a food product, which inhibits Helicobacter pylori adhesion, invasion, IL-8 secretion, and NF-κB activation, effectively targeting both antibiotic-sensitive and multidrug-resistant strains.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If antibiotics and proton pump inhibitors are used to treat Helicobacter pylori infection, then the eradication rate can be improved, but side effects and antibiotic resistance increase

Engineering Contradiction:

Improveeradication rateVSAvoidside effects and antibiotic resistance

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces Lactobacillus acidophilus as an intermediary substance that mediates the interaction between the host and Helicobacter pylori. The probiotic bacteria produce lactic acid and other substances that create an unfavorable environment for H. pylori, thereby eliminating the need for direct antibiotic intervention and reducing side effects and resistance

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent replaces the mechanical/chemical system of antibiotics and proton pump inhibitors with a biological system based on probiotic bacteria. Instead of using chemical drugs to kill or inhibit H. pylori, the treatment uses live Lactobacillus acidophilus that naturally competes with and suppresses the pathogen through biological mechanisms

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Reliability

If triple or quadruple therapy with multiple antibiotics is used, then the eradication rate can be improved, but the complexity of treatment and risk of resistance increase

Engineering Contradiction:

Improveeradication rateVSAvoidtreatment complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent extracts and eliminates the complex combination of multiple antibiotics from the treatment regimen. By isolating and using a single probiotic strain (Lactobacillus acidophilus), the treatment simplifies to a single agent that provides effective therapy without the complexity and resistance risks associated with triple or quadruple therapy

Inventive Principle:

Principle #2Taking out (Extraction)

3Reliability

If antibiotics are administered for Helicobacter pylori infection, then the infection can be treated, but gastrointestinal side effects and discomfort increase

Engineering Contradiction:

Improveinfection treatmentVSAvoidgastrointestinal side effects

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent converts the harmful effect of H. pylori infection into a beneficial situation by using Lactobacillus acidophilus that naturally competes with the pathogen. The probiotic bacteria produce lactic acid and other substances that create an unfavorable environment for H. pylori, turning the treatment into a beneficial biological competition rather than a harmful chemical attack

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The Lactobacillus composition significantly reduces Helicobacter pylori adhesion and invasion, decreases IL-8 and NF-κB expression, and inhibits COX-2 protein, providing a high eradication rate with minimal side effects, making it an effective treatment for Helicobacter pylori infections, including antibiotic-resistant strains.

Implementation Method 1

The Lactobacillus composition significantly reduces Helicobacter pylori adhesion and invasion

Methodology Applied

Scientific EffectBacterial competition:

Implementation Method 2

Lactobacillus composition for inhibiting gastritis induced by gastric helicobacter pylori

Methodology Applied

Scientific EffectProduction of inhibitory substances:

Implementation Method 3

decreases IL-8 and NF-κB expression, and inhibits COX-2 protein

Methodology Applied

Scientific EffectInhibition of inflammatory response:

Implementation Method 4

inhibits COX-2 protein

Methodology Applied

Scientific EffectProtein expression inhibition:

Data Source

PatentUS10638784B2Lactobacillus composition for inhibiting gastritis induced by gastric helicobacter pylori and use thereof

Publication Date: 2020.05.05 GENMONT BIOTECH

AI summary

The present invention provides a pharmaceutical composition and a food product for inhibiting gastritis induced by gastric Helicobacter pylori, comprising Lactobacillus selected from a group composed of Lactobacillus rhamnosus GM-020 (also known as GMNL-74) with deposited number CCTCC M203098; Lactobacillus acidophilus GMNL-185 with deposited number CCTCC M2017764; and Lactobacillus plantarum GMNL-662 with deposited number CCTCC M2016571; and any two of the above bacteria.